Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)

被引：0
|
作者：
Stenehjem, David D.
Parikh, Kinjal
Batten, Julia Anne
Van Atta, Joan
Crispin, Hilda
Sageser, Daniel S.
Grossmann, Kenneth F.
Wang, Junfeng
Tantravahi, Srinivas Kiran
Samlowski, Wolfram E.
Agarwal, Neeraj
机构：
[1] Univ Utah, Coll Pharm, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84112 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
476
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2).
    Batten, Julia Anne
    Samlowski, Wolfram E.
    Parikh, Kinjal
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Tantravahi, Srinivas Kiran
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).
    Stenehjem, David D.
    Toole, Michael
    Merriman, Joseph
    Parikh, Kinjal
    Daignault, Stephanie
    Scarlett, Sarah
    Esper, Peg
    Skinner, Katherine
    Udager, Aaron
    Tantravahi, Srinivas Kiran
    Straubhar, Alli M.
    Agarwal, Archana M.
    Van Atta, Joan
    Grossmann, Kenneth F.
    Samlowski, Wolfram E.
    Redman, Bruce G.
    Agarwal, Neeraj
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2)
    Straubhar, Alli M.
    Stenehjem, David D.
    Parikh, Kinjal
    Merriman, Joseph
    Crispin, Hilda
    Sendlinathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Agarwal, Archana M.
    Tantravahi, Srinivas Kiran
    Samiowski, Wolfram E.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2)
    Parikh, Kinjal
    Stenehjem, David D.
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Samlowski, Wolfram E.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
    Clark, Joseph
    Morse, Michael A.
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC)
    Agarwal, Neeraj
    Parikh, Kinjal
    Tantravahi, Srinivas Kiran
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Samlowski, Wolfram E.
    Grossmann, Kenneth F.
    Wang, Junfeng
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)
    Merriman, Joseph
    Parikh, Kinjal
    Tantravahi, Srinivas Kiran
    Straubhar, Alli M.
    Agarwal, Archana M.
    Sendilnathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Grossmann, Kenneth F.
    Samlowski, Wolfram E.
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
    Fishman, M.
    Dutcher, J. P.
    Clark, J., I
    Alva, A.
    Miletello, G. P.
    Curti, B.
    Agarwal, Neeraj
    Hauke, R.
    Mahoney, K. M.
    Moon, H.
    Treisman, J.
    Tykodi, S. S.
    Daniels, G.
    Morse, M. A.
    Wong, M. K. K.
    Kaufman, H.
    Gregory, N.
    McDermott, D. F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [9] High-dose interleukin-2 (HD IL-2) for metastatic renal Cell carcinoma (mRCC): Contemporary utilization trends in the United States
    Allard, Christopher B.
    Gelpi-Hammerschmidt, Francisco
    Harshman, Lauren Christine
    Faiena, Izak
    Modi, Parth K.
    Chung, Benjamin I.
    Singer, Eric A.
    Chang, Steven L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry
    Clark, Joseph
    Morse, Michael
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345